INTRODUCTION AND OBJECTIVES MATERIAL AND METHODS RESULTS CONCLUSION

Slides:



Advertisements
Similar presentations
Date of download: 6/28/2016 Copyright © 2016 American Society of Anesthesiologists. All rights reserved. Increased interleukin (IL)-10 release induced.
Advertisements

Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Bacterial persistence
Setting-up a model of intracellular infection by Pseudomonas aeruginosa for the pharmacodynamic evaluation of antibiotic activity. J. Buyck1, O. Jolois2,
studies with Caco-2 cells and THP-1 macrophages
Phenotypic, genotypic and proteomic characterization of J774 macrophages upon chronic exposure to fluoroquinolone antibiotics.
Activities of Daptomycin (DAP), Vancomycin (VAN) and Linezolid (LDZ) alone or in combination with Fusidic acid (FUS) in an in vitro dynamic model of.
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
A-052 Antibiotic (AB) activity against Pseudomonas aeruginosa (PA) with Normal or Mucoïd Phenotypes in an Artificial Sputum Medium (ASM) in vitro Biofilm.
Activity of tobramycin in combination with clarithromycin
Introduction Results Aim of the study Methods References Conclusion
Intracellular Infection of THP-1 Human Macrophages by Staphylococcus aureus and Role of Haemolysins Mailling adresse: Aurélie Olivier.
Comparison of the intracellular and extracellular activities of approved and novel antistaphylococcal antibiotics using a pharmacodynamic model exploring.
The association between anti-PcrV titers and protective effects against P. aeruginosa in PcrV vaccinated mice Saeko Hamaoka1, Yoshifumi Naito1, Hideya.
A small molecule candidate for antibiotic co-therapy in the fight against persistence Valerie Defraine1, V. Liebens1, T. Swings1, R. Corbau2, A. Marchant2,
Mix with THP-1 macrophages Overnight bacterial suspension
Products > NCI-H1299 Transfection Reagent (Lung Adenocarcinoma)
Type III secretion system (TTSS) INTRODUCTION AND OBJECTIVES
Wafi Siala1,2, Françoise Van Bambeke1 , Thomas Vanzieleghem2
Activity of 9 antibiotics against intracellular forms of S. pneumoniae
Introduction & Purpose Results Conclusions
FUS, VAN and LZD injected twice (T0 and T12); DAP injected once (T0).
Introduction Results Aim Methods References Conclusion
Co-medications Improve Moxifloxacin (MXF) Activity in Models of Pneumococcal Naïve and Induced Biofilms (BF) N. M. Vandevelde1, M. Van Obbergh1, P.M. Tulkens1,
Products > 4T1 Transfection Reagent (Breast Cancer Cells, CRL-2539)
Background and objectives
Comparative in vitro activity of temocillin and other β-lactams
Activity and Pharmacodynamic (PD) Evaluation of Ceftazidime-Avibactam (CAZ-AVI) against Extracellular and Intracellular Forms of CAZ-susceptible and CAZ-resistant.
Inhibitors of type three secretion system [TTSS] protect against Pseudomonas aeruginosa cellular toxicity by inhibiting the transcription of TTSS Mailing.
Mapping French population [1]
Julien Buyck, Paul M. Tulkens and Françoise Van Bambeke
Julien Buyck, Paul M. Tulkens and Françoise Van Bambeke
Debaditya Das, Françoise Van Bambeke, Paul M. Tulkens
Extracellular activity Intracellular activity
Abstract Results Methods Background Conclusions References
Products > PC-12 Transfection Reagent (Rat Pheochromocytoma Cells)
cellular accumulation (24h) Cstatic (LZD/RDZ ratio)
Products > AsPC-1 Transfection Reagent (Pancreatic Beta Cells)
Products > NIH3T3 Transfection Reagent (Swiss Mouse Fibroblasts)
Apoptosis induced by aminoglycosides (AGs) in cultured cells : comparison between gentamicin (GEN) and amikacin (AMK) using incubated and electroporated.
Incubation (with antibiotic)
Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells  Mouldy Sioud,
Of a Pig-related ST-398 Methicillin-Resistant S. aureus (A-MRSA)
EV0626 Cellular pharmacokinetics of gepotidacin (GSK )
A-045 Identification of the Efflux Transporter of Ciprofloxacin in Murine Macrophages: Studies with Ciprofloxacin-Resistant Cells Béatrice Marquez, Nancy.
Products > HUH-7 Transfection Reagent (Liver Cancer Cells)
Abstract Results Aim of the study Methods Background Conclusions
Difference log CFU from time 0
INTRODUCTION METHODS CONCLUSIONS REFERENCES
Products > C2C12 Transfection Reagent (Mouse Myoblast Cells)
1200 Brussels - Belgium Temocillin is not substrate for OprD2 porin from Pseudomonas aeruginosa H. Chalhoub1,
Electron microscopy: intracellular infection of THP-1 by S. aureus
Activity of Moxifloxacin against Staphylococcus aureus in Models of Persistent Infections (Intracellular Survival, Biofilms) Mailing address: P.M. Tulkens.
Products > Keratinocyte Transfection Reagent (Keratinocytes)
Products > A375 Transfection Reagent (Melanoma Cells, CRL-1619)
M.P. Mingeot-Leclercq, P.M. Tulkens, F. Van Bambeke
Intracellular models of infection to evaluate antibiotic activity
Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells  Mouldy Sioud,
Products > NCI-H441 Transfection Reagent (Lung Adenocarcinoma)
Coordinate Regulation of Bacterial Virulence Genes by a Novel Adenylate Cyclase- Dependent Signaling Pathway  Matthew C. Wolfgang, Vincent T. Lee, Meghan.
Volume 21, Issue 8, Pages (August 2014)
Volume 23, Issue 3, Pages (March 2016)
Products > NCI-H358 Transfection Reagent (Bronchioalveolar Cells)
Products > LS-174T Transfection Reagent (Colon Adenocarcinoma)
A Major Role for Capsule-Independent Phagocytosis-Inhibitory Mechanisms in Mammalian Infection by Cryptococcus neoformans  Cheryl D. Chun, Jessica C.S.
Volume 7, Issue 5, Pages (May 2010)
An Inhibitor of Gram-Negative Bacterial Virulence Protein Secretion
Discussion and Future Work
Translocation of a Vibrio cholerae Type VI Secretion Effector Requires Bacterial Endocytosis by Host Cells  Amy T. Ma, Steven McAuley, Stefan Pukatzki,
Presentation transcript:

INTRODUCTION AND OBJECTIVES MATERIAL AND METHODS RESULTS CONCLUSION  The 8-hydroxyquinoline INP1855 reduces Type Three secretion system (T3SS)-dependent virulence of Pseudomonas aeruginosa in vitro and in vivo A. Anantharajah1, E. Faure2,3, J.M. Buyck1, C. Sundin4, T. Lindmark4, PM.Tulkens1, M.P. Mingeot-Leclercq1, B. Guery2,3 and F. Van Bambeke1 1 Cellular and Molecular Pharrmaclogy, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium; 2 Lille-2 University hospital, Lille, France, 3Host-Pathogen translational Research group Pseudomonas aeruginosa, Lille, France; 4 Creative Antibiotics, Umea, Sweden ID 182 Mailing address: Françoise Van Bambeke av. Mounier 73, B1.73.05 1200 Brussels – Belgium francoise.vanbambeke@uclouvain.be INTRODUCTION AND OBJECTIVES MATERIAL AND METHODS Because of the alarming increase of resistance to current antibiotics and of the lack of novel drugs acting on multiresistant strains, new therapeutic approaches need to be explored, among which the inhibition of virulence mechanisms. T3SS is a major virulence factor in Pseudomonas aeruginosa (P.a) that allows the translocation of effector proteins from the bacterial cytoplasm directly into the eukaryotic host cells, contributing to the establishment and dissemination of acute infections [1]. The 8-hydroxyquinolines have shown inhibitory activity against T3SS of Yersinia and Chlamydia spp [2]. In this study, we evaluated the activity of INP1855 against P.a in vitro and in vivo. Bacterial strains: CHA (clinical isolate with high expression of T3SS) and CHA∆ExsA (deletion of T3SS regulon). Eukaryotic cells: human alveolar epithelial A549 cells and THP-1 monocytes. Mice: C57BL6. Chemical: INP1855 Growth inhibition assay: Optical density (620 nm) of the bacterial suspension Cell viability (eucaryotic cells): lactate dehydrogenase (LDH) release Motility assay (bacteria): swarming in LB agar 0.5% plate. Internalization assay: Bacteria pre-treated with INP1855 (3 h) and opsonised with human serum (1 h). Phagocytosis initiated with 10 CFU/ cell for 2 h (THP-1 cells) in medium containing 60 µM of INP1855 (elimination of non-phagocytised bacteria by incubation with 100 µg/mL gentamicin (1 h). After washing, cells were lysed in water and aliquots plated for CFU counting [3]. T3SS transcription assay: (1) the bioluminescence of the reporter strain CHA pC lux (constructed by fusion of luxCDABE to the promoter of the regulator operon exsCEBA [4]) in the presence of THP-1 cells or A549 cells over time of incubation with 60 µM of INP1855, (2) the levels of T3SS genes expression by RT-PCR in CHA strain in the presence of INP1855 60 µM. T3SS functionality : Detection of ExoS by Western Blot In vivo assay. Mouse model of acute lung aggression induced by CHA with co-instillation of bacteria and INP1855 200 µM. After 16 h, mice were sacrificed and different parameters were evaluated (weight gain, bacterial burden, lung lesion, bacterial dissemination and bronchoalveolar lavage cellularity). MW = 382.4 pKa = 5.75 and 8.02 (zwitterionic at pH 7) log P = 3.59 log D pH 7 = 2.23 INP1855 (8-hydroxyquinoline) calculated with Reaxys RESULTS INP1855 is not toxic for eukaryotic cells up to 60 µM, neither for bacteria at 200 µM INP1855 decreases T3SS-mediated virulence INP1855 reduces flagellar motility A CHA T3SS-dependent phagocytosis inhibition A Eukaryotic cells P.aeruginosa T3SS-dependent cytotoxicity A549 cells Figure 3 : Effect of INP1855 on cytotoxicity induced by P. aeruginosa strains. (A) A549 cells and (B) THP-1 cells were incubated with bacteria +/- INP1855 60 µM during 7h (A549) or 5h (THP-1). Values are mean ± SD (n=3). ***p<0.001 CHA + INP1855 B B THP-1 monocytes Fiigure 5: Effect of INP1855 on P. aeruginosa motility. The bacterial strains (A.CHA or B.ExsA) were grown with 60 µM of INP1855 for 3h. The area was determined using the software quantity one. Values are mean ± SD (n=3). ** p<0.01, *** p<0.001 Figure 1 : percentage of LDH release induced by INP1855 after 5h (THP-1 monocytes) or 7h (A549 cells) of incubation. Mean ± SD (n=3). Dotted line : 60 µM Figure 2 : Growth curve in presence of 200 µM of INP1855 Figure 4: Effect of INP1855 on THP-1 monocytes internalization of CHA. Values are mean ± SD (n=3). * p<0.05, ***<0,001 INP1855 decreases T3SS transcription without affecting QS system INP1855 impairs ExoS secretion INP1855 increases mice survival and bacterial clearance A B C CHA + INP1955 A B ExoS CHA ExsA TOTAL THP-1 monocytes A549 cells SUPERNATANT Figure 7 : Effect of INP1855 on T3SS functionality. ExoS was detected in bacterial culture or in bacteria-free supernatant by western blot Figure 6 : (A et B) Effect of INP1855 on T3SS transcriptional activation of exsCEBA operon. Reporter strain CHA pC lux was incubated with 60 µM of INP1855 for 10h in A549 cells (A) and in THP1- cells (B). Luminescence was measured over time. Dotted line: time selected for further experiments. (C) Gene expression evaluated by RT-PCR. CHA strain was incubated with 60 µM of INP1855 or DMSO in LB supplemented with EGTA 5 mM and MgCl2 20 mM. Mean ± SD (n=2) C D CONCLUSION INP1855 protects epithelial and phagocytic cells from T3SS-induced toxicity and is also effective in vivo. It inhibits both secretion of T3SS toxins and flagellar motility, suggesting a molecular target common to these two secretion systems. Although further studies are needed to better characterize its mode of action, our data highlights a potential interest for IN1855 as anti-pseudomonal agent. P.aeruginosa T3SS transcription  Motility  E F Flagellum T3SS ExoS secretion REFERENCES Cytotoxicity  Phagocytosis  [1] Hauser, Nature Reviews Microbiology 2009; 7:654–65. [2] Enquist et al, Bioorganic & Medicinal Chemistry Letters 2012; 22:3550-53 [3] Buyck et al, Antimicrobial Agents & Chemotherapy 2013; 57:2310-8. [4] Shen et al, Infection & Immunity 2006; 74:1121-9 Eukaryotic cell ACKOWLEDGMENTS Decreased functionality of T3SS as potential mechanism of action of INP1855: direct or indirect inhibition of the T3SS export apparatus and of flagellar basal body (which show a high degree of similarity) causing a concomitant decrease in motility, toxin secretion and T3SS transcription (ExsE, the repressor of the transcriptional factor ExsA, being translocated via the T3SS) a reduction in toxicity of P. aeruginosa for the host cells and an increased phagocytosis (demonstrated in vitro). a reduction in pulmonary lesions and infection dissemination observed in vivo We thank M.C Cambier, V. Mohymont and P. Muller for technical assistance. We thank Pr. Toussaint (GREPI EA2938, Grenoble, France) for the kind gift of CHA and CHA pC lux strains. A. Anantharajah is doctoral fellow of the Belgian Fonds de la recherche scientifique (F.S.R-FNRS) This work was supported by the Belgian Fonds de la Recherche Scientifique and the and Interuniversity Attraction Poles Programme of the Belgian Science Policy Office. Figure 8: Survival assay and in vivo assay at 16 h. Mice infected by CHA were treated with DMSO or INP1855 200 µM. A. Survival assay. B. Weigh gain C. Lung injury assessed by alveolar capillary barrier permeability D. Bacterial burden in CFU/lung. E. Cell count from bronchoalveolar lavage liquid F. Bacterial dissemination assessed by spleen cultures homogenates. Values are mean ± SD (n=5). *p<0.05, **p<0.01, ***p<0.001 This poster will be made available for download after the meeting: http://www.facm.ucl.ac.be/posters.htm